Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune is a promising biotech company due to its focus on creating novel treatments for chronic inflammatory diseases, such as AD and UC. Despite a recent setback in one of its trials, the company's assets, EVO301 and EVO756, have shown potential in generating high sales and could greatly increase shareholder value. With a strong financial position and experienced management team, Evommune has the potential for long-term success in the growing AD market.

Bears say

Evommune is a biotech company with potential treatments for inflammatory diseases. While their lead candidates show promise in clinical trials, their stock outlook is negative due to potential risks and uncertainties. Upcoming data readouts and potential mergers and acquisitions could greatly impact their stock value, but significant setbacks have also been experienced in the past.

Evommune Inc (EVMN) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 9 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.